Because recent studies have reported that inhibition of HIF-1α can overcome hypoxia-mediated sorafenib resistance in HCC [20], we tested whether miR-338-3p could sensitize HCC cells to sorafenib treatment. The gene discussed is HIF1A; the disease is hepatocellular carcinoma.